A Phase I Study of Human Umbilical Cord-Mesenchymal Stem Cells for Pneumoconiosis

Shenzhen Hornetcorn Bio-technology Company, LTD1 site in 1 country10 target enrollmentJune 2016

ConditionsPneumoconiosis

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Pneumoconiosis
Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD
Enrollment: 10
Locations: 1
Primary Endpoint: Severity of adverse events
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for Pneumoconiosis.

Detailed Description

Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into mature cells typical of several tissues, which have been confirmed in in vivo and in vitro experiments. To investigate the effects of hUC-MSC treatment for Pneumoconiosis, 10 patients with Pneumoconiosis will be enrolled and receive 4 times of hUC-MSC transplantation.

Registry

clinicaltrials.gov

Start Date

June 2016

End Date

October 2017

Last Updated

9 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Shenzhen Hornetcorn Bio-technology Company, LTD

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The patient who have signed the informed consent document;
•Clinical and radiological evidence of liver cirrhosis.

Exclusion Criteria

•Pregnant women or lactating mothers;
•History of neurological disease, head injury or psychiatric disorder;
•Patients with positive human immunodeficiency (HIV) at screening indicative of current of pass infection;
•With malignant tumors;
•Abnormal blood coagulation, combine other tumor or special condition;
•Patients who had participated in other clinical trials within three months prior to this study.